Global Health Ltd

Global Health Ltd (Medanta) announced its FY26 results, reporting a 19.6% YoY increase in consolidated total income to ₹45,089 million. EBITDA (ex-Noida) grew by 18.6% YoY to ₹11,343 million with margins of 25.7%. Profit After Tax increased by 15.1% YoY to ₹5,541 million. The Board recommended a final dividend of ₹0.50 per share. Medanta Noida, now fully operational, reported revenue of ₹906 million and an EBITDA loss of ₹783 million. Q4 FY26 saw the highest ever quarterly total income of ₹11,958 million.

Global Health Ltd's board approved the audited standalone and consolidated financial results for FY26 and recommended a final dividend of ₹0.50 per share. The board also appointed Mr. Kedar Ashok Apte as ‘Chief Marketing & Growth Officer’ and Mr. Jagdeep Singh as ‘General Counsel’ effective May 14, 2026. Ms. Richa Singh resigned from her position as SMP, effective May 20, 2026. The audit report is unmodified and contains no qualifications.

Global Health Limited's Board of Directors, in a meeting held on May 14, 2026, approved the audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2026. The board recommended a final dividend of ₹0.50 (25%) per equity share of face value ₹2 each, subject to shareholder approval at the upcoming AGM. The record date for dividend eligibility will be announced separately. Additionally, Mr. Kedar Ashok Apte and Mr. Jagdeep Singh were appointed as Chief Marketing & Growth Officer and General Counsel, respectively, effective May 14, 2026. The resignation of Ms. Richa Singh as SMP was noted, effective May 20, 2026.

Global Health Limited (GHL) has approved its audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2026. The board has recommended a final dividend of ₹0.50 (25%) per equity share, subject to shareholder approval at the AGM. The company also announced the appointment of Mr. Kedar Ashok Apte as Chief Marketing & Growth Officer and Mr. Jagdeep Singh as General Counsel, both effective May 14, 2026. The resignation of Ms. Richa Singh as SMP of the Company w.e.f. May 20, 2026 was noted.

Global Health Limited's board approved audited standalone and consolidated financial results for FY26 and recommended a final dividend of ₹0.50 per equity share (25%) subject to shareholder approval at the AGM. The board also appointed Mr. Kedar Ashok Apte as ‘Chief Marketing & Growth Officer’ and Mr. Jagdeep Singh as ‘General Counsel’ effective May 14, 2026. Ms. Richa Singh resigned as SMP effective May 20, 2026.

Global Health Ltd's Nomination & Remuneration Committee approved the grant of 10,000 ESOPs to one employee under the GHL LTIP 2024 plan on May 11, 2026. The options have an exercise price of ₹960 each and can be exercised within 3 years from the vesting date. Each option will result in the allotment of one equity share of ₹2 each. The meeting commenced at 10:45 A.M. and concluded at 11:35 A.M.

Global Health Ltd has scheduled a Board of Directors meeting on May 14, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The board will also consider and recommend a final dividend, if any, subject to shareholder approval. The trading window is closed from April 1, 2026, and will reopen 48 hours after the results are declared.

Global Health Limited (Medanta) announced the takeover of an 80-bedded Cancer Hospital in Indore, Madhya Pradesh, through a Business Transfer Agreement (BTA) with Asian Institute of Oncology Private Limited. The acquisition, valued at ₹30 crores, includes the assignment of a long-term lease. This strategic move strengthens Medanta's presence in Central India, complementing its existing 175-bedded multi-specialty hospital in Indore. Located just 500 meters from the current facility, the new hospital will enable Medanta to launch a comprehensive oncology program, enhancing its specialty offerings. The integration is expected to drive operational synergies, optimize capacity utilization, and improve patient flow across both facilities, reinforcing Medanta's commitment to advanced, patient-centric healthcare in the region.

Global Health Limited (Medanta) announced the takeover of an 80-bedded Cancer Hospital in Indore, Madhya Pradesh, through a Business Transfer Agreement (BTA). This acquisition, costing ₹30 crores including a long-term lease assignment, strengthens Medanta's presence in Central India and complements its existing 175-bedded multi-specialty hospital in the city. The newly-built facility, strategically located near the current Medanta Indore hospital, will enable the launch of a comprehensive oncology program. The integration is expected to drive operational synergies, optimize capacity utilization, and improve patient flow across both facilities, enhancing Medanta's specialized high-quality care offerings in the region.

Global Health Ltd (GHL) announced its Board approved the acquisition of a 79-bedded Cancer Care Hospital in Indore from Asian Institute of Oncology Private Limited for ₹30 crores in cash. The acquisition, expected to complete before September 30, 2026, will add to GHL's Medanta network, increasing its bed capacity by 79. The target hospital, which had a turnover of ₹19.9 million in FY24-25, is strategically located 500 meters from GHL's existing Indore facility, promising seamless integration and operational synergies. The deal will be funded by internal accruals and debt, strengthening Medanta's presence and specialized cancer care offerings in the region.